Summary:
A PHASE IIb, MULTICENTER, RANDOMIZED,
DOUBLE-BLIND, PARALLEL GROUP, PLACEBO CONTROLLED
STUDY TO EVALUATE THE
EFFICACY, SAFETY AND TOLERABILITY OF
BASMISANIL (RO5186582) AS ADJUNCTIVE
TREATMENT IN PATIENTS WITH COGNITIVE
IMPAIRMENT ASSOCIATED WITH
SCHIZOPHRENIA TREATED WITH
ANTIPSYCHOTICS
Qualified Participants Must:
• Male or female subjects aged between 18 and 50 years
•
Fluent in English
Qualified Participants May Receive:
Compensation for time and gas.